What does the assisted dying legislation mean for pharmacy? The Terminally Ill Adults (End of Life) Bill still has a long way to go before becoming law and pharmacy organisations have unresolved questions about what it might mean for pharmacy practice.…
UK medicines regulation disincentivising investment in research development, finds survey The Association of the British Pharmaceutical Industry’s survey results accompany 12 recommendations for improving the Medicines and Healthcare Products Regulatory Agency’s effectiveness as a UK medicines regulator.…
Will reshoring medicines manufacturing solve shortages in the UK? In the United States and some European countries, drug manufacturing is being brought home to mitigate shortages of critical medicines, but would similar action in the UK shore up supply resilience?…
NICE overturns decision on blood cancer treatment elranatamab Elranatamab is now recommended as a fourth-line treatment for relapsed and refractory multiple myeloma, according to updated guidance from the National Institute for Health and Care Excellence.…
Free pharmacy advice saves 38 million GP appointments a year, CPE audit finds Just over half of patients given unfunded pharmacy consultations said they would otherwise have contacted their GP.…
High deprivation areas given funding to boost structured medication reviews, says HIN The Health Innovation Network said that 25 primary care networks would be funded to provide supportive materials that had been shown to improve SMR outcomes.…
NICE rejects second Alzheimer’s disease treatment for NHS use Clinical trial evidence reveals that there are “significant health risks” linked to donanemab, with a third of patients experiencing amyloid-related imaging abnormalities as a result of brain swelling and bleeding.…
RPS to survey members before responding to government consultation on NHS ten-year plan The Royal Pharmaceutical Society said it wants the government to place supporting patient access to community pharmacies at the heart of any increase in neighbourhood health services.…
Manufacturer withdraws treatment for sickle cell disease following concern over deaths Pfizer's withdrawal is based on data that suggest “an imbalance in vast-occlusive crises and fatal events which require further assessment”.…
Regulator misses fitness-to-practise timeliness standard for sixth year in a row The Professional Standards Authority said the General Pharmaceutical Council “is still taking too long to progress fitness-to-practise investigations”.…